Ceftazidime Intravitreal Solution Recalled for Sterility Assurance Failure
Vital Care Compounder is recalling Ceftazidime intravitreal injection solutions due to manufacturing conditions that cannot guarantee product sterility. Affected lots were distributed to patients in Alabama, Louisiana, Mississippi, and Tennessee.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall involving sterile injectable ophthalmic product with manufacturing process unable to guarantee sterility. No illnesses or injuries reported; hazard is theoretical under rubric constraint. Intravitreal injections are risk-of-harm products where injury has not been reported, qualifying for score 3.
Plain-English summary
Vital Care Compounder is recalling specific lots of Ceftazidime intravitreal 2.25 mg/0.1 mL injection solution. The recall affects three lots (65434, 66349, and 66868) with beyond-use dates of October 13, November 5, and November 18, 2022, respectively.
The products are being recalled because FDA inspection determined they were produced in a manner that cannot guarantee the sterility of products represented as sterile.
The affected products were distributed in Alabama, Louisiana, Mississippi, and Tennessee. Patients who received these recalled injections should consult their healthcare provider regarding potential need for follow-up evaluation or alternative treatment options.
The recalled product
- Product
- CEFTAZIDIME INTRAVITREAL 2.25MG/0.1ML Solution, 0.5 mL syringe, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402
- Manufacturer
- Pharmacy Plus, Inc. dba Vital Care Compounder
- Category
- Drug — Ophthalmic / Injectable
- Affected units
- 12
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lots: 65434
- BUD: 10/13/2022
- 66349
- BUD: 11/05/2022
- 66868
- BUD: 11/18/2022
Distribution
Part of a larger recall action
This product is one of 32 recalled by Pharmacy Plus, Inc. dba Vital Care Compounder under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 32 products in this recall →Related recalls
Same manufacturer · Pharmacy Plus, Inc. dba Vital Care Compounder
See all →- HighCompounded Semaglutide Injection Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2023-04-26
- HighAcetylcysteine eye drops recalled for sterility assurance defect
FDA (Drugs) · 2022-11-09
- HighPrescription Injectable Medication Recalled for Sterility Assurance Failure
FDA (Drugs) · 2022-11-09
- HighFDA Recalls Vital Care Autologous Tears Serum Due to Sterility Assurance Failure
FDA (Drugs) · 2022-11-09
- HighMoxifloxacin Preservative-Free Eye Drops Recalled for Sterility Assurance Failure
FDA (Drugs) · 2022-11-09
Same hazard · lack of sterility assurance
See all →- SevereNAD+ Pre-Filled Syringes Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2025-07-02
- ModerateTirzepatide Injections Pre-filled Syringe Recalled for Sterility Assurance
FDA (Drugs) · 2025-07-02
- HighHydromorphone Injection Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2024-04-03
- HighPHENYLephrine HCl Injectable Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2024-04-03
- HighFentanyl Injection Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11